Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQianfoshan Hospital
About this trial
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.
Eligibility criteria
Qualifiers
Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis.
Meets the diagnostic criteria for fungal-sensitized asthma.
Disqualifiers
Human immunodeficiency virus infection.
Malignant tumor.
Blood system disease.
autoimmune system disease.
Trial design
Treatments tested in this trial
Treatment groups
140 Participants
are divided into 3 treatment groupsSponsors and collaborators
Qianfoshan Hospital
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Collaborator
Fudan University
Collaborator
Guizhou Provincial People's Hospital
Collaborator
The First Hospital of Jilin University
Collaborator
Qilu Hospital of Shandong University
Collaborator
Source ClinicalTrials.gov